Clinical-stage biotech harnessing AI and machine learning to decode innate immunity, inflammasome biology, and neuroinflammation via the Gut-Brain Axis (GBA) to identify, de-risk, and prioritize therapeutic programs for highly debilitating inflammatory Gastrointestinal (GI), and hepatobiliary disorders. We leverage a proprietary AI-based platform, GBAnk™, a product of AlphaMeld®, which has currently identified over 20 programs that have the potential to transform the treatment of these diseases. The first three programs that have been prioritized for clinical testing include: • INVA8001, a first-in-class, oral, novel small molecule mast cell degranulation inhibitor with proven human safety, for the treatment of moderate to severe Ulcerative Colitis (UC), and Eosinophilic Gastrointestinal Disorders (EGIDs) • INVA8002, a novel colon-targeted formulation of a small molecule inhibitor of the 5-HT3 receptor with demonstrated human safety for the treatment of moderate to severe UC as an add-on therapy to an anti-TNF regimen • INVA8003, a first-in-class, novel small molecule pan-inflammasome inhibitor (ASC) with a broad anti-inflammatory impact on inflammatory disorders • The remaining early-stage programs have been queued for validation studies and will be developed with a strategic partner.